1-(甲氧基甲基)环丁烷羧酸 | 1082766-22-0

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 中文名称: 1-(甲氧基甲基)环丁烷羧酸
• 英文名称: 1-(methoxymethyl)cyclobutanecarboxylic acid
• 英文别名: 1-(Methoxymethyl)cyclobutane-1-carboxylic acid
• CAS: 1082766-22-0
• 化学式: C₇H₁₂O₃
• mdl: MFCD11505299
• 分子量: 144.17
• InChiKey: RCYWGWYQQBABKC-UHFFFAOYSA-N

物化性质

• 沸点：
  231.8±13.0 °C(Predicted)
• 密度：
  1.147±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  10
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.857
• 拓扑面积：
  46.5
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• WGK Germany：
  3

反应信息

• 作为反应物：
  描述：

  1-(甲氧基甲基)环丁烷羧酸 、 7-methoxy-4-(1-methyl-3-phenyl-1H-pyrazol-4-yl)quinazolin-6-amine 在 吡啶 、 1-丙基磷酸酐 作用下， 生成 N-(7-methoxy-4-(1-methyl-3-phenyl-1H-pyrazol-4-yl)quinazolin-6-yl)-1-(methoxymethyl)cyclobutane-1-carboxamide
  参考文献：
  名称：

  [EN] EGFR INHIBITORS
  [FR] INHIBITEURS D'EGFR

  摘要：

  The present disclosure provides a compound represented by structural formula (A) or (I): or a pharmaceutically acceptable salt thereof useful for treating a cancer.

  公开号：

  WO2023196283A1

文献信息

• ISOXAZOLE DERIVATIVE AS MUTATED ISOCITRATE DEHYDROGENASE 1 INHIBITOR
  申请人：Daiichi Sankyo Company, Limited

  公开号：EP3202766A1

  公开（公告）日：2017-08-09

  It has been found that a compound of the general formula (I) having an isoxazole skeleton has excellent inhibitory activity against mutant IDH1 protein and inhibits the production of 2-HG by this protein, while the compound is also capable of effectively inhibiting the growth of various tumors expressing the protein. In the formula, R1, R2, R3, Y, and Z are as defined in claim 1.

  研究发现，具有异噁唑骨架的通式（I）化合物对突变型 IDH1 蛋白具有极好的抑制活性，并能抑制该蛋白产生 2-HG，同时该化合物还能有效抑制表达该蛋白的各种肿瘤的生长。式中，R1、R2、R3、Y 和 Z 如权利要求 1 所定义。
• Isoxazole derivative as mutant isocitrate dehydrogenase 1 inhibitor
  申请人：Daiichi Sankyo Company, Limited

  公开号：US10040791B2

  公开（公告）日：2018-08-07

  It has been found that a compound of the general formula (I) having an isoxazole skeleton has excellent inhibitory activity against mutant IDH1 protein and inhibits the production of 2-HG by this protein, while the compound is also capable of effectively inhibiting the growth of various tumors expressing the protein. In the formula, R1, R2, R3, Y, and Z are as defined in claim 1.

  研究发现，具有异噁唑骨架的通式（I）化合物对突变型 IDH1 蛋白具有极好的抑制活性，并能抑制该蛋白产生 2-HG，同时该化合物还能有效抑制表达该蛋白的各种肿瘤的生长。 式中，R1、R2、R3、Y 和 Z 如权利要求 1 所定义。
• ISOXAZOLE DERIVATIVE AS MUTANT ISOCITRATE DEHYDROGENASE 1 INHIBITOR
  申请人：Daiichi Sankyo Company, Limited

  公开号：US20170313696A1

  公开（公告）日：2017-11-02

  It has been found that a compound of the general formula (I) having an isoxazole skeleton has excellent inhibitory activity against mutant IDH1 protein and inhibits the production of 2-HG by this protein, while the compound is also capable of effectively inhibiting the growth of various tumors expressing the protein. In the formula, R 1 , R 2 , R 3 , Y, and Z are as defined in claim 1.
• [EN] EGFR INHIBITORS<br/>[FR] INHIBITEURS D'EGFR
  申请人：[en]BLUEPRINT MEDICINES CORPORATION

  公开号：WO2023196283A1

  公开（公告）日：2023-10-12

  The present disclosure provides a compound represented by structural formula (A) or (I): or a pharmaceutically acceptable salt thereof useful for treating a cancer.